皮炎外瓶霉临床和环境分离株对6种常用抗真菌药物的敏感性测定

Abstract

Abstract:

Objective To investigate the in vitro susceptibility of 16 strains of Exophiala dermatitidis to 6 commonly used antifungal agents. Methods The Clinical and Laboratory Standards Institute （CLSI） M27-A2 protocol was carried out to determine the MICs of terbinafine （TRB）, itraconazole （ITC）, amphotericin B （AMB）, fluconazole （FLC）, voriconazole （VRC）, and caspofungin （CAS） to 16 strains of E. dermatitidis, and E-test was performed to determine those of VRC, ITC and AMB. Besides, the minimal fungicidal concentrations （MFCs） of the above antifungal agents to the 16 strains of E. dermatitidis were further assessed. The activity of TRB in combination with ITC and VRC against E. dermatitidis was also estimated. Results The MIC ranges of TRB, VRC, ITC, AMB, FLC, and CAS were 0.125 - 0.25 mg/L, 0.25 - 0.5 mg/L, 2.0 mg/L, 2.0 mg/L, 16 - 32 mg/L and 16 - 64 mg/L respectively as shown by M27-A2 microdilution assay, while the MIC ranges of VRC, ITC and AMB, as determined by E-test, were 0.032 - 0.094 mg/L, 0.047 - 0.5 mg/L and 0.125 - 3.0 mg/L, respectively. The MFC ranges of TRB, VRC, ITC, AMB and FLC were 0.125 - 0.5 mg/L, 0.25 - 0.5 mg/L, 2.0 - 4.0 mg/L, 2.0 - 4.0 mg/L and 16 - 64 mg/L, respectively. No synergism in the acitivity against E. dermatitidis was observed for the combination of TBR with ITC or VRC. Conclusion E. dermatitidis is susceptible to TRB, ITC, AMB, and VRC, but less sensitive to both FLC and CAS.

Key words: Exophiala dermatitidis, Antifungal drugs, In vitro susceptibility test

References

参考文献 [1] Ajello L, Georg L K, Steigbigel R T, et al. A case of phaeohyphomycosis caused by a new species of Phialophora.[J]. Mycologia,1974,66(3):490-498. [2] Revankar S G. Therapy of infections caused by dematiaceous fungi.[J]. Expert Rev Anti Infect Ther,2005,3(4):601-612. [3] Laniado-Laborin R, Cabrales-Vargas M N. Amphotericin B: side effects and toxicity.[J]. Rev Iberoam Micol,2009, 26(4):223-227. [4] Denning D W. Echinocandin antifungal drugs.[J]. Lancet,2003,362(9390):1142-1151. [5] Li D M, de Hoog G S. Cerebral phaeohyphomycosis--a cure at what lengths?[J]. Lancet Infect Dis,2009,9(6):376-383. [6] Revankar S G, Patterson J E, Sutton D A, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis.[J]. Clin Infect Dis,2002,34(4):467-476. [7] National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts----second edition. Approved standard M27-A2. NCCLS, Wayne, PA, USA. 2002. [8] Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.[J]. J Clin Microbiol,2001,39(3):954-958. [9] Mcginnis M R. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology.[J]. J Am Acad Dermatol,1983,8(1):1-16. [10] Rossmann S N, Cernoch P L, Davis J R. Dematiaceous fungi are an increasing cause of human disease.[J]. Clin Infect Dis,1996,22(1):73-80. [11] Oztas E, Odemis B, Kekilli M, et al. Systemic Phaeohyphomycosis Caused by Exophiala dermatitidis Resembling Primary Sclerosing Cholangitis.[J]. J Med Microbiol,2009,58(9):1243-1246 [12] Alabaz D, Kibar F, Arikan S, et al. Systemic phaeohyphomycosis due to Exophiala (Wangiella) in an immunocompetent child.[J]. Med Mycol,2009, 47(6):653-657 [13] Chang X, Li R, Yu J, et al. Phaeohyphomycosis of the central nervous system caused by Exophiala dermatitidis in a 3-year-old immunocompetent host.[J]. J Child Neurol,2009,24(3):342-345. [14] Filizzola M J, Martinez F, Rauf S J. Phaeohyphomycosis of the central nervous system in immunocompetent hosts: report of a case and review of the literature.[J]. Int J Infect Dis,2003,7(4):282-286. [15] Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review.[J]. Expert Opin Pharmacother,2009,10(16):2723-2733. [16] Hope W W, Billaud E M, Lestner J, et al. Therapeutic drug monitoring for triazoles.[J]. Curr Opin Infect Dis,2008,21(6):580-586. [17] Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.[J]. Clin Infect Dis,2003,37(5):728-732.

In vitro susceptibility testing of 16 strains of Exophiala dermatitidis to 6 commonly used antifungal agents

PDF

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Metrics

Comments

Recommended 10

[1]	Lu-juan GAO Yi Sun. Effects of photodynamic therapy alone or in combination with antifungal agents on the apoptosis of planktonic and biofilm cells of Exophiala dermatitidis [J]. Chinese Journal of Dermatology, 2018, 51(7): 515-518.
[2]	. In vitro susceptibility testing of Penicillium marneffei against several antifungal agents [J]. Chinese Journal of Dermatology, 2012, 45(4): 234-237.
[3]	. Mutation analysis of ERG11 gene in Candida albicans isolates from patients with acquired immunodeficiency syndrome （AIDS） [J]. Chinese Journal of Dermatology, 2012, 45(1): 32-34.
[4]	WANG Xue-Jun LU Xue-lian . Species profile and anti-yeast susceptibility of pathogenic fungi isolated from infants and young children with dermatocandidiasis [J]. Chinese Journal of Dermatology, 2008, 41(8): 509-.
[5]	JIANG Tao, CAO Yu, ZHAO Xiuhua. Study on Antifungal Action of 22 Effective Components of Chinese Herbs and Application of New Preparations [J]. Chinese Journal of Dermatology, 1999, 32(5): 316-318.